Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Acquired dysregulation of dopamine homeostasis reproduces features of Parkinson’s disease
Meghan L. Bucher, Caitlyn W. Barrett, Connor Moon, et al.
npj Parkinson s Disease (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Oxidative Stress and Neuroinflammation in Parkinson’s Disease: The Role of Dopamine Oxidation Products
Sasanka Chakrabarti, Marco Bisaglia
Antioxidants (2023) Vol. 12, Iss. 4, pp. 955-955
Open Access | Times Cited: 53
Potential roles of gut microbiota and microbial metabolites in Parkinson’s disease
Shen-Yuan Zheng, Haixia Li, Rui-Chen Xu, et al.
Ageing Research Reviews (2021) Vol. 69, pp. 101347-101347
Closed Access | Times Cited: 73
Intervention of Polydopamine Assembly and Adhesion on Nanoscale Interfaces: State‐of‐the‐Art Designs and Biomedical Applications
Xiyue Xie, Jia Tang, Yuxin Xing, et al.
Advanced Healthcare Materials (2021) Vol. 10, Iss. 9
Closed Access | Times Cited: 59
Human neural stem cell-derived extracellular vesicles protect against Parkinson’s disease pathologies
Eun Ji Lee, Yoori Choi, Hong J. Lee, et al.
Journal of Nanobiotechnology (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 53
Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders
Rachel M. Wise, Annika Wagener, Urban M. Fietzek, et al.
Neurobiology of Disease (2022) Vol. 175, pp. 105920-105920
Open Access | Times Cited: 48
In vivoreduction of age-dependent neuromelanin accumulation mitigates features of Parkinson’s disease
Marta González-Sepúlveda, Joan Compte, Thaïs Cuadros, et al.
Brain (2023) Vol. 146, Iss. 3, pp. 1040-1052
Open Access | Times Cited: 24
Synaptic vesicle glycoprotein 2C enhances vesicular storage of dopamine and counters dopaminergic toxicity
Meghan L. Bucher, Amy R. Dunn, Joshua M. Bradner, et al.
European Journal of Neuroscience (2024) Vol. 59, Iss. 10, pp. 2483-2501
Open Access | Times Cited: 9
Targeting α‐synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease
Md. Ezazul Haque, Mahbuba Akther, Shofiul Azam, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 1, pp. 23-45
Open Access | Times Cited: 54
Targets to Search for New Pharmacological Treatment in Idiopathic Parkinson’s Disease According to the Single-Neuron Degeneration Model
Sandro Huenchuguala, Juan Segura‐Aguilar
Biomolecules (2024) Vol. 14, Iss. 6, pp. 673-673
Open Access | Times Cited: 7
Enhanced tyrosine hydroxylase activity induces oxidative stress, causes accumulation of autotoxic catecholamine metabolites, and augments amphetamine effects in vivo
Laura M. Vecchio, Patricia Sullivan, Amy R. Dunn, et al.
Journal of Neurochemistry (2021) Vol. 158, Iss. 4, pp. 960-979
Open Access | Times Cited: 33
From cradle to grave: neurogenesis, neuroregeneration and neurodegeneration in Alzheimer’s and Parkinson’s diseases
Debia Wakhloo, Sameehan Mahajani, Jane Oberhauser, et al.
Neural Regeneration Research (2022) Vol. 17, Iss. 12, pp. 2606-2606
Open Access | Times Cited: 26
Decoding Neurodegeneration: A Review of Molecular Mechanisms and Therapeutic Advances in Alzheimer’s, Parkinson’s, and ALS
Corneliu Toader, Călin Petru Tătaru, Octavian Munteanu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 23, pp. 12613-12613
Open Access | Times Cited: 6
Structural bioinformatics studies of serotonin, dopamine and norepinephrine transporters and their AlphaFold2 predicted water-soluble QTY variants and uncovering the natural mutations of L->Q, I->T, F->Y and Q->L, T->I and Y->F
Taner Karagöl, Alper Karagöl, Shuguang Zhang
PLoS ONE (2024) Vol. 19, Iss. 3, pp. e0300340-e0300340
Open Access | Times Cited: 5
N -acetylcysteine increases dopamine release and prevents the deleterious effects of 6-OHDA on the expression of VMAT2, α-synuclein, and tyrosine hydroxylase
Roine El‐Habta, Sara af Bjerkén, Ana Virel
Neurological Research (2024) Vol. 46, Iss. 5, pp. 406-415
Open Access | Times Cited: 4
Gastrodin relieves Parkinson's disease-related motor deficits by facilitating the MEK-dependent VMAT2 to maintain dopamine homeostasis
Meihuan Zhao, Yongtao Zhou, Ruilin Sheng, et al.
Phytomedicine (2024) Vol. 132, pp. 155819-155819
Closed Access | Times Cited: 4
From 2D to 3D: Development of Monolayer Dopaminergic Neuronal and Midbrain Organoid Cultures for Parkinson’s Disease Modeling and Regenerative Therapy
Yee Jie Yeap, Tng J. W. Teddy, Mok Jung Lee, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2523-2523
Open Access | Times Cited: 9
Biochemical Neuroadaptations in the Rat Striatal Dopaminergic System after Prolonged Exposure to Methamphetamine Self-Administration
Subramaniam Jayanthi, Bruce Ladenheim, Patricia Sullivan, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 10092-10092
Open Access | Times Cited: 14
Research on Temperature-Switched Dopamine Electrochemical Sensor Based on Thermosensitive Polymers and MWCNTs
Haixiu Wang, Zufei Feng, Fupeng Lin, et al.
Polymers (2023) Vol. 15, Iss. 6, pp. 1465-1465
Open Access | Times Cited: 7
A systematic exploration of unexploited genes for oxidative stress in Parkinson’s disease
Takayuki Suzuki, Hidemasa Bono
npj Parkinson s Disease (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 2
The impact of gamma-radiation on the cerebral- and cerebellar- cortex of male rats’ brain
Fatma R. Algeda, Noaman Abdelatief Eltahawy, Shereen M. Shedid, et al.
Brain Research Bulletin (2022) Vol. 186, pp. 136-142
Closed Access | Times Cited: 11
Neuroprotective Properties of Quinone Reductase 2 Inhibitor M-11, a 2-Mercaptobenzimidazole Derivative
М. В. Воронин, Ilya A. Kadnikov, Л. Ф. Зайнуллина, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 13061-13061
Open Access | Times Cited: 13
Measurement of LRRK2 Kinase Activity by Proximity Ligation Assay
Matthew T. Keeney, Eric K. Hoffman, Timothy J. Greenamyre, et al.
BIO-PROTOCOL (2021) Vol. 11, Iss. 17
Open Access | Times Cited: 12
Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice
Chiara Domenicale, Daniela Mercatelli, Federica Albanese, et al.
Biomedicines (2022) Vol. 10, Iss. 4, pp. 881-881
Open Access | Times Cited: 8
Neuromelanin: Its role in the pathogenesis of idiopathic Parkinson's disease and potential as a therapeutic target
R. S. Mitra, Lavienraj Premraj, Tien K. Khoo
Parkinsonism & Related Disorders (2023) Vol. 112, pp. 105448-105448
Closed Access | Times Cited: 4
Selective dopaminergic neurotoxicity modulated by inherent cell-type specific neurobiology
Fatema Currim, Reeya Tanwar, Josephine M. Brown-Leung, et al.
NeuroToxicology (2024) Vol. 103, pp. 266-287
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top